The most relevant recent area of investor attention is commercial adoption of infection-prevention products; this does not establish an independently verified price catalyst on 29 October.
The most relevant recent area of investor attention is contract delivery and public-sector commissioning; this does not establish an independently verified price catalyst on 29 October.
EDX Medical is focused on diagnostic technologies, where validation, laboratory adoption, partnerships and recurring test volumes are key to commercial progress. Investors will be watching evidence of customer uptake, regulatory compliance, cash consumption, intellectual-property development and the timeline from technical capability to repeatable revenue. …
Fusion Antibodies provides antibody engineering and discovery services. Recent October updates included a contract win and a research and trading update. Investors will be watching the size and timing of contract revenue, repeat business, laboratory utilisation, cash runway, customer concentration and whether its technology …
ImmuPharma remains a development-stage biotechnology story, with recent updates covering its P140 programme, patent work and development support for Kapiglucagon. Investors will be watching clinical and regulatory milestones, partner engagement, cash resources and the pace at which research programmes can reach value-defining evidence. This …
Oxford Nanopore Technologies plc shares fell 0.77% today, according to the market data provided, dropping 1.8p to233.2p.
OXB Company plc shares fell 1.87% today, according to the market data provided, dropping 10p to525p.
In an announcement released at 07:00 on 29 October 2026, HUTCHMED said the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia (ITP). The company said the designation "underscores the potential of sovleplenib …
Haleon released two regulatory announcements on the London Stock Exchange this morning. At 07:00 it issued its "2026 Q3 Trading Statement" covering the third quarter of the year ending 31 December 2026. At 07:05 it followed with a separate announcement confirming the commencement of …
Cardiogeni, a UK clinical-stage biotechnology company traded on the AQSE Growth Market under the ticker CGNI, issued an update on the timing of its audited annual accounts for the financial year ended 31 March 2026.